92
Participants
Start Date
January 28, 2019
Primary Completion Date
August 31, 2024
Study Completion Date
August 31, 2024
Observational PK study
The study team will examine the PK and tolerability of the new HRZ 50/75/150 mg dispersible tablet in children with TB with and without HIV coinfection. Intensive PK testing will be performed after at least 4 weeks of treatment in children on first-line anti-TB therapy using the new pediatric HRZ FDC tablet.
Kwame Nkrumah University of Science and Technology, Kumasi
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
University of Florida
OTHER